Croma-Pharma Launched New Dermal Filler Product
The company has introduced saypha volume prime Lidocaine to replace its previous version in international markets.
Updated on Sept. 25, 2026 in Beauty
Live Poll
Do you trust that new medical aesthetic products represent real improvements for patients?
Croma-Pharma has debuted a new cross-linked hyaluronic acid dermal filler designed for midface volumization and the treatment of nasolabial folds. The product, saypha volume prime Lidocaine, will replace the company's existing saypha volume Lidocaine solution.
Why it matters
This rollout aims to provide a more versatile solution with expanded indications for aesthetic treatments. The transition is part of the company's efforts to update its portfolio of injectable products.
The new filler is a cross-linked hyaluronic acid product tested on nearly 500 patients. Croma-Pharma, which operates in 80 countries, produced over 130 million syringes in 2026.
The players
Croma-Pharma
This family-owned pharmaceutical company based in Leobendorf, Austria, specializes in the development and production of hyaluronic acid-based aesthetic products.
The details
The rollout of the new product begins gradually in late September 2026 based on specific local market regulations. Croma-Pharma, based in Leobendorf, Austria, employs approximately 400 people to manage its global operations.
Timeline
Croma-Pharma was founded in 1976.
The company produced over 130 million syringes in 2026.
The new dermal filler was announced on September 25, 2026.
The transition to the new product begins at the end of September 2026.
Culture Shift
This move reflects the broader industry trend of prioritizing specialized, cross-linked hyaluronic acid formulations for facial aesthetics. As the aesthetic medicine market grows, manufacturers are increasingly replacing legacy products with updated versions that offer expanded treatment indications.
Patients may notice their providers switching to the updated filler as regional registrations are completed. The product remains intended for specialized medical use in midface volumization and treating nasolabial folds.
The takeaway
The transition to this new formulation demonstrates how manufacturers focus on clinical data to ensure products remain competitive in aesthetic medicine. Patients should consult with their practitioners to understand how the product update affects their specific treatment plans.
Further reading
Learn more about the latest developments in the aesthetic industry by visiting our Beauty section.
Source note: This article includes information reported by Iberonews.
Live Poll
Do you trust that new medical aesthetic products represent real improvements for patients?
